The Wall Street Journal announced August 13 that Pfizer (NYSE:PFE) filed plans to sell up to 20% of its animal-health unit in the first half of 2013. Credit Suisse estimates the spinoff could bring Pfizer as much as $3.8 billion initially and much more once it sells the remaining 80% stake in Zoetis. Pfizer shareholders should be elated at the news. Here's why.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Share Repurchases
Pfizer's up 35% in the last 52 weeks. However, long-term it hasn't done nearly as well as its peers. For instance, over the 10-year period ended August 10, Pfizer averaged an annual total return of -0.22%, 225 basis points worse than Merck (NYSE:MRK) and 463 points worse than Johnson & Johnson (NYSE:JNJ). Therefore, share repurchases and anything else that can juice its earnings is welcome news. Assuming it sells the entire animal-health unit for $18 billion over the next 12-24 months it could buyback as many as 752 million shares at present prices, which would reduce the total number of shares outstanding by approximately 10% and increase earnings per share by 12%. With the loss of market exclusivity for Lipitor, the repurchase plans should help offset any loss in sales.

SEE: A Breakdown Of Stock Buybacks


Business Focus
Pfizer estimates that vaccines and medicines for animals is a $22 billion dollar market. If so, its 2011 revenues of $4.2 billion make it the largest manufacturer in the world with a 19% market share. Furthermore, because animal-health research and development is faster, less expensive and more predictable than human pharmaceuticals, it's a great business to be a part of.

In addition, while human pharmaceuticals often involve insurance, most animal-health customers pay out-of-pocket, making it a more reliable business. With so much of Pfizer's focus on human pharmaceuticals, opportunities in emerging markets while substantial are likely not being exploited to their full potential. Giving the animal-health unit its independence is definitely what's best for Pfizer shareholders as both companies will be able to focus on their respective businesses.

SEE: Pets Are Profitable

Spinoffs
Phil Rosenthal of the Chicago Tribune wrote a great article at the end of June summarizing why spinoffs make so much sense. Utilizing the experience of Joe Cornell, founder of Chicago's Spinoff Advisors, Rosenthal points out that spinoffs have historically outperformed the S&P 500 by a substantial margin.

Furthermore, citing examples like the 2005 spinoff of CBS (NYSE:CBS) by former parent Viacom (Nasdaq:VIA), the spinoff often does better than the parent because independence forces its management team to survive and thrive on its own. In addition, once free of its parent, it's able to secure capital without having to beg. That makes a huge difference in a company's success.

The Bottom Line
As I understand the Pfizer/Zoetis IPO, Class A shares will be exchanged in return for debt held by the underwriters (debt retired) and then those shares will be sold to the public. They're doing this in order to avoid paying tax on the cash. Eventually, Pfizer will likely distribute its Class B shares, which are worth 10 times the votes, to Pfizer shareholders in the form of dividends. In short, Pfizer shareholders appear to be the big winners in this arrangement.

SEE: Cashing In On Corporate Restructuring


At the time of writing, Will Ashworth did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Will Virtusa Corporation's Stock Keep Chugging in 2016? (VRTU)

    Read a thorough review and analysis of Virtusa Corporation's stock looking to project how well the stock is likely to perform for investors in 2016.
  2. Stock Analysis

    Analyzing Porter's Five Forces on JPMorgan Chase (JPM)

    Examine the major money-center bank holding firm, JPMorgan Chase & Company, from the perspective of Porter's five forces model for industry analysis.
  3. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  4. Stock Analysis

    Analyzing Dish Network's Return on Equity (ROE) (DISH, TWC)

    Analyze Dish Network's return on equity (ROE), understand why it has vacillated so greatly in recent years and learn what factors are influencing it.
  5. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  6. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  7. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  8. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  9. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  10. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center